Drug Profile
Linezolid
Alternative Names: L - Pfizer; Lin - Pfizer; PNU 100766; U 100766; Zyvox; Zyvoxam; ZyvoxidLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Acetamides; Antibacterials; Oxazolidinones; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bacterial infections; Community-acquired pneumonia; Diabetic foot ulcer; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections; Nosocomial pneumonia; Skin and soft tissue infections; Vancomycin-resistant enterococcal infections
Most Recent Events
- 25 Jun 2015 Pfizer terminates a phase III trial in Optic nerve disorders in USA, Italy and Sweden (NCT00359632)
- 01 Jan 2014 Seoul National University Hospital initiates a phase II trial in Tuberculosis (pulmonary) in South Korea (NCT01994460)
- 22 Oct 2010 Efficacy data from a phase IV trial (ZEPHyR) in Nosocomial pneumonia due to MRSA released by Pfizer